Sweet-like syndrome secondary to chimeric antigen receptor T-cell therapy for multiple myeloma: a case report

BackgroundChimeric antigen receptor T-cell therapy targeting B-cell maturation antigen (BCMA CAR-T) has significantly improved outcomes in relapsed/refractory multiple myeloma (R/RMM), yet its spectrum of immune-related adverse events continues to be defined. Among these, cutaneous toxicities are no...

Descrición completa

Detalles Bibliográficos

Principais autores:	Xianfeng Ouyang, Yan Huang, Yanfang Huang, Si Yi, Yulu Wang, Linchun Fang
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2026-05-01
Series:	Frontiers in Immunology
Assuntos:	BCMA chimeric antigen receptor T-cell therapy cutaneous toxicity multiple myeloma sweet’s syndrome
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fimmu.2026.1844119/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!